コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fference between the involved and uninvolved free light chain.
2 damage mediated by misfolded immunoglobulin free light chains.
3 rapidly reduce the secretion of nephrotoxic free light chains.
4 but also circulate independently in blood as free light chains.
5 e difference between involved and uninvolved free light chains.
6 lonal immunoglobulin or abnormal circulating free light chains.
7 ow molecular weight proteins that include Ig free light chains.
8 um or urine protein electrophoresis or serum free light chains), a life expectancy of at least 12 mon
9 of risk models, including flow cytometry and free-light chain analyses, for predicting risk of progre
11 s, immunofixation electrophoresis, and serum free light-chain analysis were performed on all sera col
13 tigated whether a concomitant abnormality in free light chain and immunoglobulin levels could identif
14 individuals had an increase of at least one free light chain and met criteria for light-chain MGUS.
16 retic peptide (NT-proBNP), echocardiography, free light chains and CMR with T1 and ECV mapping at dia
17 eld include the introduction of an assay for free light chains and the use of novel antiplasma cell a
18 rum and urine protein electrophoresis, serum free light chain, and/or quantitative immunoglobulins).
21 y discuss recent advances in AL, such as the free light-chain assay and the role of immunoglobulin li
23 rategies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents
27 in sign, paramagnetic rim lesions, and kappa free-light chain concentrations in CSF can be used, when
28 g of 82 patients, changes in serum and urine free-light-chains corresponded, but urine became negativ
31 of restarting therapy, median difference of free light chain (dFLC) was 9.9 mg/dL (42% of diagnosis
32 a difference between involved and uninvolved free light chains (dFLC) >50 mg/L were included in 15 ce
33 involved amyloidogenic and uninvolved serum-free light chains (dFLC) < 10 mg/L (low dFLC response) p
34 ence between involved minus uninvolved serum free light chains (dFLC) has been established as an inva
35 a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of ba
36 sma cell dyscrasia (difference between serum free light chains [dFLC]) >180 mg/L as an overall strong
37 e difference between involved and uninvolved free light chains (dFLCs; > 50 mg/L) in only two thirds
38 easurable disease (measured by assessment of free light chains), Eastern Cooperative Oncology Group (
39 lectrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all sa
40 ignificance (MGUS), as detected by the serum free light chain (FLC) assay increases the risk of progr
43 iple myeloma (SMM), as detected by the serum free light chain (FLC) assay, indicates an increased ris
44 pplicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of
48 ively evaluated serial paraprotein and serum free light chain (FLC) measurements and found that 258 o
50 e median IgM paraprotein was 8 g/L and serum free light chain (FLC) ratio was abnormal in 77 (88%) of
51 bortezomib-based in 58%), 67% achieved serum free light chain (FLC) response, including very good par
53 cantly associated with progression: abnormal free light-chain (FLC) ratio (<0.26 or >1.65), M-protein
54 d to deposition of monoclonal immunoglobulin free light chains (FLCs) and directly contributes to mor
55 een the extent of reduction of amyloidogenic free light chains (FLCs) and improvement in survival.
59 d serum concentration of immunoglobulin (Ig) free light chains (FLCs) in both atopic and non-atopic i
60 e), elevated kappa and lambda immunoglobulin free light chains (FLCs) in peripheral blood are associa
61 ssayed monoclonal (M)-proteins, kappa/lambda free light chains (FLCs) in prediagnostic obtained up to
62 an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; however, it
63 e, estimated glomerular filtration rate, and free light chains (FLCs) measurements together with 24-h
64 igh concentrations of circulating monoclonal free light chains (FLCs) produced by a clonal expansion
65 result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein
66 cell activation or clonality: immunoglobulin free light chains (FLCs), soluble CD30 (sCD30), and mono
67 trophoresis/immunofixation) and kappa-lambda free light chains (FLCs), we determined longitudinally t
68 ciation between circulating kappa and lambda free light chains (FLCs), which are markers of B-cell dy
69 the production of monoclonal immunoglobulin free light chains (FLCs), which coprecipitate with Tamm-
74 A baseline difference of involved/uninvolved free light chains > 50 mg/L (odds ratio [OR], 0.21, P
75 te, and electrolytes measurements as well as free light chain, if available, and urine electrophoresi
77 ysis (HCO-HD) can remove large quantities of free light chain immunoglobulin from serum, but its effe
80 ed any independent relationship between high free light chain, immunoglobulins and hospital mortality
81 knowledge, abnormalities and associations of free light chain in critically ill adults with sepsis ha
83 corresponded, but urine became negative for free-light-chains in 26 patients, whereas it remained ab
84 8; 95% CI, 1.61-4.14; P < .001), and a kappa free light chain index of 6.1 or more (HR, 2.79; 95% CI,
85 eep normalization of involved immunoglobulin free light chains is necessary to maximize chances of re
86 Bence Jones protein in urine (immunoglobulin free-light-chains) is characteristic of light-chain mult
87 ytosis, t(14;18) translocation, and abnormal free light chains k/ ratios were detected by flow cytome
88 day 1, high free light chain lambda and high free light chain kappa were seen in 46.5% and 75.3% of t
91 quantify levels of Fab+Fc, the Fab arm, and free light chain (LC) and heavy chain (HC) fragments, we
95 , serum creatinine, serum calcium, and serum free light chain levels; serum protein electrophoresis w
96 g levels with patterns of organ involvement, free light-chain levels, the levels of cardiac biomarker
98 lasma cell dyscrasia, significant amounts of free light chains, now monoclonal proteins, present to t
99 ge, 6-24), with deep suppression in involved free light chains observed within 1 cycle of therapy, tr
100 e compared with that derived from pathologic free light chains or cTnT in patients evaluated before f
101 tolic dysfunction (p < 0.01), the pathologic free light chains (p < 0.05), cardiac troponin-T (cTnT)
102 terized by the overproduction of an unstable free light chain, protein misfolding and aggregation, an
103 relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clon
104 n myeloma has been defined by a normal serum free light chain ratio (SFLCR) in addition to the standa
106 need for BM studies; 10% with a normal serum-free light chain ratio had BM plasma cells more than or
107 inuria >=1.5 g/d, hematuria, and an elevated free light chain ratio increase the likelihood of findin
108 a requirement for normalization of the serum-free light chain ratio to negative immunofixation studie
109 iomarkers (monoclonal protein concentration, free light chain ratio, age, creatinine concentration, a
110 sis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detect
113 ht predictors: diabetes, affected/unaffected free light chain ratio, urinary protein (g/24 hours), po
115 is was done for all samples with an abnormal free light-chain ratio or abnormal protein electrophores
116 Light-chain MGUS was defined as an abnormal free light-chain ratio with no IgH expression, plus incr
117 .3%) of 18,357 people tested had an abnormal free light-chain ratio, of whom 213 had IgH expression t
118 e isotype; monoclonal protein concentration; free light-chain ratio; and total IgG, IgM, and IgA conc
119 lasma cells, presence of a markedly abnormal free-light-chain ratio (<0.01 or >100), and reduction of
121 alysis, the combination of chemotherapy with free light chain removal through high-cutoff hemodialysi
122 cells in the proximal tubule of the kidney, free light chains, renal fibroblasts, and myeloma cells.
123 amide or an immunodulatory agent may improve free light chain response but raises tolerance concerns
126 M) in clinical practice, and to refine serum free light chain (sFLC) ratio cut-offs that reliably exc
128 In patients with < 50% reduction of serum free light chains (sFLCs) after 3 cycles, chemotherapy w
130 immunofixation, as well as analyses of serum free light chains, should also be performed to identify
131 eld include the availability of an assay for free light chains, the introduction of new agents which
132 fy gene defects and the measurement of serum free light chains to identify secondary hypogammaglobuli
133 ses in the rapidly changing MM markers serum free light chains, urine light chains, and bone marrow p
134 loma with measurable disease by M protein or free light chain, were aged 18-70 years, had an ECOG per
135 4, and IgM levels, as well as immunoglobulin free light chains, were measured in both patients with a
137 frequent is the precipitation of monoclonal free light chains with uromodulin in the distal tubules,